HighTide Therapeutics Inc (2511.HK)
HKD 1.11
(14.43%)
HKD 1.11
(14.43%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -959.42 Million CNY | -73.81% |
| 2022 | -261.42 Million CNY | -66.24% |
| 2021 | -157.26 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -133.02 Thousand HKD | 99.9% |
| 2024 Q1 | -134.16 Thousand HKD | 67.38% |
| 2023 Q1 | -98.25 Thousand HKD | 99.93% |
| 2023 Q4 | -276.81 Million HKD | -187064.38% |
| 2023 Q3 | -147.89 Thousand HKD | 99.92% |
| 2023 Q2 | -175.26 Million HKD | -178281.91% |
| 2023 FY | - CNY | -73.81% |
| 2022 Q2 | -125.75 Million HKD | 0.0% |
| 2022 FY | - CNY | -66.24% |
| 2022 Q4 | -135.4 Million HKD | 0.0% |
| 2021 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 1151.611% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 297.09% |